New COVID-19 Vaccine Codes: June Update

The Current Procedural Terminology (CPT®) Editorial Panel (the Panel) has approved a new vaccine administration code (0083A) for the third dose of the Pfizer vaccine product to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) in pediatric patients aged 6 months through 4 years. This code will become effective upon receiving the emergency use authorization (EUA) from the Food and Drug Administration (FDA).

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes) that features timely updates of the Panel’s actions. The last COVID-19 update was in the CPT® Assistant Special Edition: May Update (2022) in which the Moderna vaccine product (91311) and vaccine administration codes (0111A, 0112A) for pediatric patients aged 6 months through 5 years were discussed.

This issue of CPT® Assistant Special Edition introduces and provides guidance on the appropriate use of the new Pfizer vaccine administration code (0083A) for pediatric patients aged 6 months through 4 years.
**Immunization Administration for Vaccines/Toxoids**

# ⚫ 0081A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

# ● 0082A

second dose

# ● 0083A

third dose

► (Report 0081A, 0082A, 0083A for the administration of vaccine 91308) ➤

► (Do not report 0081A, 0082A, 0083A in conjunction with 91300, 91305, 91307) ➤

**Vaccines, Toxoids**

# ✓ ● 91308

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

► (Report 91308 with administration codes 0081A, 0082A, 0083A) ➤

► (Do not report 91308 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A) ➤

Previously established vaccine product code 91308 and its associated vaccine administration codes (0081A, 0082A) describe Pfizer’s COVID-19 vaccine product for pediatric patients aged 6 months through 4 years. The new vaccine administration code (0083A) should be used to report
the third dose of the primary series of Pfizer’s COVID-19 vaccine product for this patient population.

As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the Centers for Disease Control and Prevention regarding which patients should receive a COVID-19 vaccine is available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html.

Note that vaccine administration code 0083A is only intended to be reported with vaccine product code 91308. Parenthetical notes have been added following the administration and product codes to clarify the appropriate use of this new code.

To accommodate the new coding structure, Appendix Q was added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. Appendix Q has been reformatted to also include the appropriate age range for each vaccine product and the associated vaccine administration codes to assist in providing clarity for the user. The new Pfizer vaccine administration code (0083A) has been added to Appendix Q.

Additional details on the new vaccine coding structure and other pertinent information provided in multiple special editions of the CPT® Assistant for COVID-19 guidance are available at https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes

The following clinical example and procedural description reflect a typical clinical scenario for which this new code would be appropriately reported.

**Clinical Example (0083A)**

A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.
Description of Procedure (0083A)

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the third dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.